Theravance Biopharma Analyst Ratings
Theravance Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 24.78% | SVB Leerink | $12 → $14 | Maintains | Outperform |
| 11/08/2022 | 69.34% | HC Wainwright & Co. | $12 → $19 | Maintains | Buy |
| 07/25/2022 | -10.87% | Morgan Stanley | $11 → $10 | Maintains | Underweight |
| 05/23/2022 | 6.95% | SVB Leerink | → $12 | Initiates Coverage On | → Outperform |
| 03/02/2022 | -1.96% | Morgan Stanley | $10 → $11 | Maintains | Underweight |
| 02/24/2022 | 6.95% | HC Wainwright & Co. | $8 → $12 | Maintains | Buy |
| 11/05/2021 | 6.95% | JP Morgan | $7 → $12 | Upgrades | Underweight → Neutral |
| 09/16/2021 | -10.87% | Morgan Stanley | $14 → $10 | Maintains | Underweight |
| 09/16/2021 | -28.7% | HC Wainwright & Co. | $21 → $8 | Maintains | Buy |
| 09/16/2021 | -10.87% | SVB Leerink | $29 → $10 | Maintains | Outperform |
| 08/25/2021 | 24.78% | Morgan Stanley | $27 → $14 | Downgrades | Overweight → Underweight |
| 08/24/2021 | 24.78% | Cowen & Co. | $42 → $14 | Downgrades | Outperform → Market Perform |
| 08/24/2021 | 158.47% | SVB Leerink | $37 → $29 | Maintains | Outperform |
| 08/24/2021 | 60.43% | Needham | $32 → $18 | Maintains | Buy |
| 08/24/2021 | 87.17% | HC Wainwright & Co. | $32 → $21 | Maintains | Buy |
| 08/04/2021 | 229.77% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 07/16/2021 | 140.64% | Morgan Stanley | $28 → $27 | Maintains | Overweight |
| 06/28/2021 | 220.86% | SVB Leerink | $39 → $36 | Maintains | Outperform |
| 05/13/2021 | 149.55% | Morgan Stanley | $30 → $28 | Maintains | Overweight |
| 05/05/2021 | 185.2% | Needham | $40 → $32 | Maintains | Buy |
| 05/05/2021 | 247.59% | SVB Leerink | $40 → $39 | Maintains | Outperform |
| 04/01/2021 | 256.51% | SVB Leerink | $41 → $40 | Maintains | Outperform |
| 03/01/2021 | 167.38% | Morgan Stanley | $31 → $30 | Maintains | Overweight |
| 02/24/2021 | 265.42% | SVB Leerink | $35 → $41 | Maintains | Outperform |
| 12/16/2020 | 176.29% | Morgan Stanley | $32 → $31 | Maintains | Overweight |
| 11/24/2020 | 167.38% | Evercore ISI Group | → $30 | Reinstates | → Outperform |
| 11/06/2020 | 211.94% | SVB Leerink | $40 → $35 | Maintains | Outperform |
| 10/14/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 08/10/2020 | 167.38% | Piper Sandler | $35 → $30 | Maintains | Overweight |
| 08/10/2020 | 158.47% | Morgan Stanley | $30 → $29 | Maintains | Equal-Weight |
| 07/07/2020 | 158.47% | JP Morgan | → $29 | Initiates Coverage On | → Overweight |
| 06/15/2020 | 167.38% | Morgan Stanley | → $30 | Initiates Coverage On | → Equal-Weight |
| 05/13/2020 | 274.33% | Cowen & Co. | → $42 | Initiates Coverage On | → Outperform |
| 02/25/2020 | 185.2% | HC Wainwright & Co. | $30 → $32 | Maintains | Buy |
| 02/25/2020 | 211.94% | Piper Sandler | $40 → $35 | Maintains | Overweight |
| 11/06/2019 | 60.43% | Baird | $22 → $18 | Upgrades | Underperform → Neutral |
| 10/29/2019 | 122.82% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 02/08/2018 | 327.81% | Leerink Swann | $45 → $48 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 11/17/2022 | 24.78% | SVB Leerink | $12 → $14 | 维护 | 跑赢大盘 |
| 11/08/2022 | 69.34% | HC Wainwright公司 | $12 → $19 | 维护 | 买 |
| 07/25/2022 | -10.87% | 摩根士丹利 | $11 → $10 | 维护 | 体重不足 |
| 05/23/2022 | 6.95% | SVB Leerink | → $12 | 开始承保 | →跑赢大盘 |
| 03/02/2022 | -1.96% | 摩根士丹利 | $10 → $11 | 维护 | 体重不足 |
| 02/24/2022 | 6.95% | HC Wainwright公司 | $8 → $12 | 维护 | 买 |
| 11/05/2021 | 6.95% | 摩根大通 | $7 → $12 | 升级 | 减重→中性 |
| 09/16/2021 | -10.87% | 摩根士丹利 | $14 → $10 | 维护 | 体重不足 |
| 09/16/2021 | -28.7% | HC Wainwright公司 | $21 → $8 | 维护 | 买 |
| 09/16/2021 | -10.87% | SVB Leerink | $29 → $10 | 维护 | 跑赢大盘 |
| 08/25/2021 | 24.78% | 摩根士丹利 | $27 → $14 | 评级下调 | 增持→减持 |
| 08/24/2021 | 24.78% | 考恩公司 | $42 → $14 | 评级下调 | 跑赢→市场表现 |
| 08/24/2021 | 158.47% | SVB Leerink | $37 → $29 | 维护 | 跑赢大盘 |
| 08/24/2021 | 60.43% | 李约瑟 | $32 → $18 | 维护 | 买 |
| 08/24/2021 | 87.17% | HC Wainwright公司 | $32 → $21 | 维护 | 买 |
| 08/04/2021 | 229.77% | SVB Leerink | $36 → $37 | 维护 | 跑赢大盘 |
| 07/16/2021 | 140.64% | 摩根士丹利 | $28 → $27 | 维护 | 超重 |
| 06/28/2021 | 220.86% | SVB Leerink | $39 → $36 | 维护 | 跑赢大盘 |
| 05/13/2021 | 149.55% | 摩根士丹利 | $30 → $28 | 维护 | 超重 |
| 05/05/2021 | 185.2% | 李约瑟 | $40 → $32 | 维护 | 买 |
| 05/05/2021 | 247.59% | SVB Leerink | $40 → $39 | 维护 | 跑赢大盘 |
| 04/01/2021 | 256.51% | SVB Leerink | $41 → $40 | 维护 | 跑赢大盘 |
| 03/01/2021 | 167.38% | 摩根士丹利 | $31 → $30 | 维护 | 超重 |
| 02/24/2021 | 265.42% | SVB Leerink | $35 → $41 | 维护 | 跑赢大盘 |
| 12/16/2020 | 176.29% | 摩根士丹利 | $32 → $31 | 维护 | 超重 |
| 11/24/2020 | 167.38% | Evercore ISI集团 | → $30 | 恢复 | →跑赢大盘 |
| 11/06/2020 | 211.94% | SVB Leerink | $40 → $35 | 维护 | 跑赢大盘 |
| 10/14/2020 | — | 摩根士丹利 | 升级 | 等重→超重 | |
| 08/10/2020 | 167.38% | 派珀·桑德勒 | $35 → $30 | 维护 | 超重 |
| 08/10/2020 | 158.47% | 摩根士丹利 | $30 → $29 | 维护 | 等重 |
| 07/07/2020 | 158.47% | 摩根大通 | → $29 | 开始承保 | →超重 |
| 06/15/2020 | 167.38% | 摩根士丹利 | → $30 | 开始承保 | →等重 |
| 05/13/2020 | 274.33% | 考恩公司 | → $42 | 开始承保 | →跑赢大盘 |
| 02/25/2020 | 185.2% | HC Wainwright公司 | $30 → $32 | 维护 | 买 |
| 02/25/2020 | 211.94% | 派珀·桑德勒 | $40 → $35 | 维护 | 超重 |
| 11/06/2019 | 60.43% | 贝尔德 | $22 → $18 | 升级 | 表现不佳的→中性 |
| 10/29/2019 | 122.82% | HC Wainwright公司 | → $25 | 开始承保 | →购买 |
| 02/08/2018 | 327.81% | 利林克·斯旺 | $45 → $48 | 维护 | 跑赢大盘 |
What is the target price for Theravance Biopharma (TBPH)?
Theravance Biophma(TBPH)的目标价是多少？
The latest price target for Theravance Biopharma (NASDAQ: TBPH) was reported by SVB Leerink on November 17, 2022. The analyst firm set a price target for $14.00 expecting TBPH to rise to within 12 months (a possible 24.78% upside). 6 analyst firms have reported ratings in the last year.
SVB Leerink于2022年11月17日报道了Theravance Biophma(纳斯达克：tbph)的最新目标价。这家分析公司将目标价定为14.00美元，预计TBPH将在12个月内上涨(可能上涨24.78%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Theravance Biopharma (TBPH)?
Theravance Biophma(TBPH)的最新分析师评级是多少？
The latest analyst rating for Theravance Biopharma (NASDAQ: TBPH) was provided by SVB Leerink, and Theravance Biopharma maintained their outperform rating.
对Theravance Biophma(纳斯达克代码：TBPH)的最新分析师评级由SVB Leerink提供，Theravance Biophma维持其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?
Theravance Biophma(TBPH)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Theravance Biophma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Theravance Biophma的最后一次评级是在2022年11月17日提交的，所以你应该预计下一次评级将在2023年11月17日左右的某个时候提供。
Is the Analyst Rating Theravance Biopharma (TBPH) correct?
分析师对Theravance Biophma(TBPH)的评级正确吗？
While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a maintained with a price target of $12.00 to $14.00. The current price Theravance Biopharma (TBPH) is trading at is $11.22, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Theravance Biophma(TBPH)评级保持不变，目标价在12.00美元至14.00美元之间。Theravance Biophma(TBPH)目前的交易价格为11.22美元，超出了分析师的预测区间。